SONIRE Announces First Patient Enrolled in Randomized Phase 2 ...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
TOKYO, Feb. 2, 2023 /Kyodo JBN-AsiaNet/ -- SONIRE Therapeutics Inc. (hereinafter referred to as "SONIRE"), based in Tokyo, announces that it has commenced a randomized phase 2 study for the treatment of unresectable pancreatic cancer with SONIRE's next-generation High-Intensity Focused Ult...
Authors: LATEST ASIANET NEWS RELEASES